<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">
Go Back

Biodesix to Present at 2011 Biotech Showcase


Biodesix, Inc. announces that Paul Beresford, Ph.D., Vice President, Business Development and Strategic Marketing will present at the 2011 Biotech Showcase conference taking place January 10-12th at the Parc 55 Wyndham in San Francisco, California. Biodesix’ presentation will occur on Monday, January 10th, at 2:15 p.m. Pacific time.  Dr. Beresford will provide a corporate overview and brief discussion of the Company’s unique approach to developing tests for personalized medicine.  Interested parties may request a copy of the presentation by sending an email to bizdev@biodesix.com.

About Biodesix

Biodesix is a fully integrated molecular diagnostic company focused on advancing personalized medicine by providing physicians with tools for earlier disease detection, more accurate diagnosis, and better therapeutic guidance.  In 2009, Biodesix launched VeriStrat®, a serum proteomic test that helps physicians guide treatment for patients with non-small cell lung cancer.  VeriStrat is based on ProTS®, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles that characterize a patient’s condition or likely outcome in response to therapy.  The ProTS® platform has broad application and provides the foundation for collaborations with leading researchers as well as partnerships with biotechnology and pharmaceutical companies seeking to develop companion diagnostics and improve the targeting of their therapies. For more information about Biodesix, please visit the Company’s website at www.Biodesix.com .

About the Biotech Showcase™

Now in its third year, Biotech Showcase™ will feature corporate presentations by 195 innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration.  The showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action.  Public and private investors are invited to attend the showcase on a complimentary basis. For more information please visit:  http://www.ebdgroup.com/bts/index.php.


Topics: Biotech Showcase, blood-based cancer test, cancer diagnostics, personalized medicine, Press Releases, serum proteomic test, liquid biopsy, lung cancer, molecular diagnostic, Non-Small Cell Lung Cancer, NSCLC, oncology